Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
History, Research, Technology & Companies
Explore the main themes, entities and connections around Definium Therapeutics. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
mindmed lsd psychedelic clinical disorder company trials phase trial 2020 study inc new definium therapeutics research 2021 announced anxiety effects
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Definium Therapeutics | Area served | Worldwide | 1.00 | infobox |
| Definium Therapeutics | Formerly | Mind Medicine Inc. / MindMed | 1.00 | infobox |
| Definium Therapeutics | Founded | May 2019; 7 years ago (2019-05), in Toronto, Canada | 1.00 | infobox |
| Definium Therapeutics | Founder | Jamon "JR" Rahn Stephen Hurst Scott Freeman Leonard Latchman | 1.00 | infobox |
| Definium Therapeutics | Headquarters | New York, U.S. | 1.00 | infobox |
| Definium Therapeutics | Industry | Biotechnology Mental health | 1.00 | infobox |
| Definium Therapeutics | ISIN | CA60255C8850 | 1.00 | infobox |
| Definium Therapeutics | Key people | Robert Barrow (CEO) | 1.00 | infobox |
| Definium Therapeutics | Key people | Daniel R Karlin, MD, MA (CMO) | 1.00 | infobox |
| Definium Therapeutics | Number of employees | 57 | 1.00 | infobox |
| Definium Therapeutics | Services | Drug development | 1.00 | infobox |
| Definium Therapeutics | Services | Psychedelic research | 1.00 | infobox |
| Definium Therapeutics | Services | Psychedelic assisted therapy | 1.00 | infobox |
| Definium Therapeutics | Subsidiaries | MindMed Discover (Basel, Switzerland) MindMed Pty Ltd. (Perth, Western Australia) | 1.00 | infobox |
| Definium Therapeutics | Traded as | Nasdaq: DFTX | 1.00 | infobox |
| Definium Therapeutics | Type | Public | 1.00 | infobox |
| Definium Therapeutics | Website | definiumtx.com | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.